Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Thyroid Neoplasms × capivasertib × Clear all

Sponsor

Conditions

Triple Negative Breast Neoplasms 2 Recurrence 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Hematologic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Endometrioid 1 Breast Neoplasms 1 Advanced Solid Malignancy, 1

Interventions

vandetanib 7 Sorafenib 6 Magnetic Resonance Spectroscopy 6 lenvatinib 5 cabozantinib 5 Sunitinib 4 Iodine-131 4 selpercatinib 3 AZD 6244 3 trametinib 2 tipifarnib 2 durvalumab 2 dabrafenib 2 alectinib 2 Triiodothyronine 2 Thyroxine 2 Thyrotropin Alfa 2 Paclitaxel 2 Nivolumab 2 Ipilimumab 2 Fluorodeoxyglucose F18 2 Everolimus 2 Bortezomib 2 Axitinib 2 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2 tremelimumab 1 temsirolimus 1 tanespimycin 1 sapanisertib 1 romidepsin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡